Radiosurgery systems maker Varian affirms its 2014 outlook with 5% year-over-year growth in Q1, even as per-share earnings fall short of expectations.
Palo Alto, Calif.-based Varian Medical (NYSE:VAR) started its fiscal year with moderate growth and a reaffirmed outlook on 2014, but per-share earnings fall short of analysts' projections.
Women's health company Hologic posts Q1 figures that beat analysts' consensus estimates even as the company swings hard into the red.
Massachusetts-based Hologic's (NSDQ:HOLX) dove into the red during its 1st quarter of 2014 on a decrease in sales.
Accuray slashes Q2 losses and ups its earnings expectations for the year, prompting a 13% boost from Wall Street.
California radiation oncology systems maker Accuray (NSDQ:ARAY) scored major Wall Street points with its 2nd quarter financial report, with shares soaring on news of lowered losses and increased guidance for the year.
Massachusetts-based Abiomed reports record Impella heart pump revenues during its 3rd quarter, with sales up 20% year-over-year.
Bay state medical device maker Abiomed (NSDQ:ABMD) reported another strong quarter, with revenues up 20% on record sales of its flagship Impella cardiac pump.
Siemens' healthcare division sees declines in the company's 1st quarter, even as total profits soar 20%.
Healthcare giant Siemens (NYSE:SI) saw declines in its healthcare division during Q1, with sales and profits down on a shaky quarter.
Haemonetics' Q3 adjusted profits remain flat year over year, but net profits soar as the company reaps the benefits of "productivity programs."
Massachusetts medical device maker Haemonetics (NYSE:HAE) this week released its 3rd-quarter earnings report, posting a major boost in profits that the company attributed to "productivity programs yielding cost efficiencies."
ResMed misses Wall Street's Q2 earnings expectations as U.S. sales fall shorter than projected.
Shares of respiratory devices maker ResMed (NYSE:RMD) dropped more than 6% today after the company reported its Q2 earnings, missing Wall Street's expectations.